R value investing economic surveys indicate that CFO

Economic surveys indicate that CFO confidence levels in value-centric firms are rising, supporting the thesis that "R value investing" will outperform in a slow-growth, high-rate environment over the next two quarters. Catalyst is a rare-disease biotech company based in Coral Gables, Florida. It has three drugs on the market targeting neurological and neuromuscular conditions, and it generated over $500 million in sales over the past four quarters. Source: Kenneth R. French, Bloomberg, and Goldman Sachs Asset Management. As of January 31, 2023. Correlations are calculated based on daily return differentials between growth-style equities and value-style equities. Correlation of 0.83 is derived from the daily returns of Fama/French H20 (Value) and L20 (Growth) portfolios formed on Book-to-Market factor, using the time range January 2, 2008 – December 31, 2019. Correlation of 0.68 is derived using the same portfolios daily returns from time range January 2, 2020, through January 31, 2023. Past performance does not guarantee future results, which may vary. Analysts predict that geopolitical tensions in commodity-producing regions will further enhance "R value investing" prospects in energy and mining stocks, as supply constraints elevate pricing power in these sectors.